These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32670103)

  • 61. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
    J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.
    Dichtel LE; Nyer M; Dording C; Fisher LB; Cusin C; Shapero BG; Pedrelli P; Kimball AS; Rao EM; Mischoulon D; Fava M; Miller KK
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558402
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression.
    Gandelman JA; Kang H; Antal A; Albert K; Boyd BD; Conley AC; Newhouse P; Taylor WD
    J Clin Psychiatry; 2018 Aug; 79(5):. PubMed ID: 30192444
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
    Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
    Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessing and measuring cognitive function in major depressive disorder.
    Ragguett RM; Cha DS; Kakar R; Rosenblat JD; Lee Y; McIntyre RS
    Evid Based Ment Health; 2016 Nov; 19(4):106-109. PubMed ID: 27935809
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder.
    Goldsmith DR; Haroon E; Woolwine BJ; Jung MY; Wommack EC; Harvey PD; Treadway MT; Felger JC; Miller AH
    Brain Behav Immun; 2016 Aug; 56():281-8. PubMed ID: 27040122
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.
    Furey ML; Drevets WC; Hoffman EM; Frankel E; Speer AM; Zarate CA
    JAMA Psychiatry; 2013 Mar; 70(3):280-90. PubMed ID: 23364679
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sex differences in the mediators of functional disability in Major Depressive Disorder.
    Carmona NE; Subramaniapillai M; Mansur RB; Cha DS; Lee Y; Fus D; McIntyre RS
    J Psychiatr Res; 2018 Jan; 96():108-114. PubMed ID: 28992527
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
    JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
    Weisler RH; Ota A; Tsuneyoshi K; Perry P; Weiller E; Baker RA; Sheehan DV
    J Affect Disord; 2016 Nov; 204():40-7. PubMed ID: 27322768
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.
    Lazowski LK; Townsend B; Hawken ER; Jokic R; du Toit R; Milev R
    BMC Psychiatry; 2014 Jul; 14():202. PubMed ID: 25030264
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.
    Levitan RD; Levitt AJ; Michalak EE; Morehouse R; Ramasubbu R; Yatham LN; Tam EM; Lam RW
    J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 30063303
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Digging deeper in the differential effects of inflammatory and psychosocial stressors in remitted depression: Effects on cognitive functioning.
    Niemegeers P; de Boer P; Schuermans J; Dumont GJH; Coppens V; Spittaels K; Claes S; Sabbe BGC; Morrens M
    J Affect Disord; 2019 Feb; 245():356-363. PubMed ID: 30423462
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful treatment with guanfacine in a long-COVID case manifesting marked cognitive impairment.
    Kondo T; Higa R; Kuniba M; Shinzato H; Takaesu Y
    Neuropsychopharmacol Rep; 2024 Jun; ():. PubMed ID: 38934345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.